Discloses a VEGF-binding molecule comprising three CDR regions, wherein CDR1 is SYSMG, CDR2 is AISKGGYKYDAVSLEG, and CDR3 is SRAYGSSRLRLADTYEY, wherein the VEGF-binding molecule is capable of blocking the interaction of human recombinant VEGFR-2 with an inhibition rate of at least 60%, and related nucleic acids, vectors, host cells, pharmaceutical compositions and therapeutic uses.